First-of-its-Kind Blood-Based Pan Cancer Early Detection Test Combines Protein Markers, Genomic and Epigenetic Features of Cancer in Blood

A first-of-its-kind blood-based pan cancer early detection test combines protein markers, genomic and epigenetic features of cancer in blood.

SeekIn Inc. (Shenzhen, China) has announced the CE (Conformité Européenne) Mark for SeekInCare Cancer Detection Kit and is now ready to launch this test in the European markets.

Nearly 10 million people died from cancer last year worldwide. The majority of cancers is found too late to be treated. Clinically validated cancer early screening tests can save lives, but only cover a few cancer types such as lung, colon, liver, breast, cervix and prostate with limited detection rate and specificity. A single test to effectively screen all cancers has been regarded as the ultimate goal for cancer screening for every person. SeekIn has an artificial intelligence-based platform that uses insights from both private and public data to identify weak cancer DNA and protein signals in the blood and trace them back to a tissue of origin. SeekIn has patents on the algorithms to reduce background noise and reveal cancer signals in blood.

SeekInCare has been developed as a pan cancer detection test that takes a panoramic view of blood cell-free cancer signatures and a multi-omics approach incorporating genomic and epigenetic alterations in conjunction with clinically validated protein biomarkers. Equipped with proprietary AI- and big data-driven CRS algorithm, SeekInCare exhibits superior effectiveness to detect dozens of cancer types at high specificity. Launched as a lab developed test (LDT) in China since late 2018, SeekInCare is intend to use for the individuals with elevated risks of cancer such as smoking, chronic hepatitis, aging, etc., in conjunction with the approved conventional single cancer type screening tests.

"This is a major step toward our mission to bring blood-based cancer early detection into mainstream cancer care management," said Mao Mao, M.D., Ph.D., SeekIn's founder and CEO. "Cancer is part of my family and I have been dedicating myself to develop cutting-edge blood-based pan cancer early detection technologies since 2014. Inspired by our clinical study in 2 million women, we took a unique approach to capture the common genomic and epigenetic features of cancer in blood, which represents one of the three major technologies to screen multiple cancer types using a tube of blood. Combining with the conventional protein markers, this test will be able to detect dozens of cancer types in asymptomatic patients when cancer is more likely to be curable. CE Marking represents a significant milestone for SeekIn in bringing SeekInCare test to the patients and healthcare providers in Europe. We will continue our efforts to meet additional regulatory requirements in Europe, and to obtain regulatory approvals in the other territories such as China and Japan."

Related Links:
SeekIn Inc. 

Visit expo >

Platinum Member

COVID-19 Rapid Test

OSOM COVID-19 Antigen Rapid Test

Magnetic Bead Separation Modules
MAG and HEATMAG

POCT Fluorescent Immunoassay Analyzer

FIA Go

New

Gold Member

Fully Automated Cell Density/Viability Analyzer

BioProfile FAST CDV